Roundup Exposure Lawsuit — What Cancer Victims Need to Know
- amber0821
- May 3
- 2 min read
Roundup Exposure Lawsuit: What Cancer Victims Need to Know About Glyphosate Risks
Roundup, the world’s most widely used herbicide, is now at the center of one of the largest mass tort litigations in U.S. history. The weed killer contains glyphosate, a chemical that the World Health Organization’s International Agency for Research on Cancer (IARC) has classified as “probably carcinogenic to humans.”
Thousands of individuals diagnosed with non-Hodgkin lymphoma and other cancers are now pursuing a Roundup exposure lawsuit, alleging that long-term use of the product led to their illness.

Roundup and Glyphosate: A Controversial History
Roundup was developed by Monsanto and acquired by Bayer in 2018.
Glyphosate is still legal in the U.S., but banned or restricted in several countries.
The EPA maintains that glyphosate is safe when used as directed, but the IARC disagrees.
In March 2025, a Georgia jury awarded $2.1 billion to a plaintiff who developed cancer after using Roundup for years — one of the largest verdicts to date.
What Illnesses Are Linked to Roundup?
The most common Roundup-related diagnosis is:
Non-Hodgkin lymphoma (NHL)
Other potential conditions under investigation include:
B-cell lymphoma
Leukemia
Multiple myeloma
Chronic lymphocytic leukemia (CLL)
Who Can File a Roundup Exposure Lawsuit?
To qualify, individuals must typically show:
Frequent or long-term Roundup use (occupational or home use)
Medical diagnosis of NHL or related cancer
Timeline that supports exposure-linked illness development
There is no bankruptcy trust yet, but lawsuits are still being filed nationwide.
How Hiatt Law Group Can Help
At Hiatt Law Group, we help cancer patients and their families:
Collect proof of Roundup exposure (work or home use)
Gather medical documentation and expert support
File and manage your Roundup exposure lawsuit
Pursue full and fair compensation for your suffering
📞 Call 662-636-6291 now for a FREE case review — no obligation, no upfront fees.
Comments